“Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer” has been added to your cart. View cart

Article: Expanding the therapeutic armamentarium in relapsed/refractory Diffuse Large B-cell Lymphoma

€3.03

SKU: product-article-44222 Category: General

Description
Reviews (0)

Description

Expanding the therapeutic armamentarium in relapsed/refractory Diffuse Large B-cell Lymphoma

Reviews

There are no reviews yet.

Be the first to review “Article: Expanding the therapeutic armamentarium in relapsed/refractory Diffuse Large B-cell Lymphoma”

You must be logged in to post a review.

Top

Article: Expanding the therapeutic armamentarium in relapsed/refractory Diffuse Large B-cell Lymphoma

Description

Reviews

Related products

Article: Highlights in respiratory oncology

Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer

Article: Highlights in breast cancer

Article: INTRODUCTION